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Background: Severe pre-eclampsia is one of the major causes of high maternal mortality rate in both developed and 
developing countries. The goals of management are to prevent progression to eclampsia thus preventing convulsions, 
to control the blood pressure and to prevent untoward effects in the foetus. The first-line option for the treatment and 
prevention of eclamptic seizures is magnesium sulphate. 
Objective: To determine the serum magnesium, urea and electrolyte levels in neonates of mothers treated with 
magnesium sulphate and compare the findings with the levels in non-exposed neonates. 
Methodology: A quasi experimental design was adopted where test subjects were neonates of mothers suffering from 
preeclampsia and severe eclampsia and were being treated with magnesium sulphate just before delivery at Pumwani 
Maternity hospital. The control group comprised neonates of hypertensive mothers without preeclampsia being 
treated using other drugs. Blood samples were obtained from the mother at onset of labor and from the neonates at 
birth and analyzed in the clinical chemistry laboratory of the University of Nairobi.  
Results:  A total of 54 mothers and their neonates were enrolled with 27 in each arm of the study. The mean maternal 
serum magnesium in the test group was significantly higher than in the control group (p = 0.008). The mean neonatal 
serum magnesium in the test group was also significantly higher compared to the control group (p = 0.008). There 
were statistically significant differences in serum sodium (p = 0.015), urea (p = 0.043) and creatinine (p = 0.008) 
levels between the maternal test and control groups. There were significant differences in serum urea (p = 0.007) and 
chloride (p = 0.017) between the neonatal test and control groups. The calcium and potassium levels were elevated in 
the test group but not to significant levels. There was a positive correlation between maternal and neonatal serum 
magnesium levels in both groups stronger in the test group (r = 0.56, p = 0.003) as compared to the control group (r = 
0.35, p = 0.087).  
Conclusion: Maternally administered magnesium sulphate raises urea and creatinine levels to significant levels in 
mothers. Calcium levels are also raised while in mothers not receiving magnesium sulphate they were slightly lower. 
In neonates the urea and chloride levels are elevated to significant levels while the calcium and potassium levels are 
not significantly elevated. We suggest monitoring of both in the immediate post-partum period. 
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1. Introduction 
Pre-eclampsia (PET) also referred to as toxemia of 
pregnancy, is defined as the development of 
hypertension accompanied by proteinuria and edema 
during the third trimester of pregnancy. In a patient 
with pre-existing essential hypertension, it is diagnosed 
if the systolic blood pressure (BP) increases by 
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30mmHg or the diastolic increases by 15mmHg. In 
severe cases, convulsions may appear and the condition 
is thus termed eclampsia.  
Severe PET is one of the major causes of high maternal 
mortality rate in both developed and developing 
countries. The goals of management are to prevent 
progression to eclampsia thus preventing convulsions, 
to control the BP by stabilizing the diastolic pressure to 
between 90-100 mmHg and to prevent untoward effects 
in the foetus.  
The first-line option for the treatment and prevention of 
eclamptic seizures is magnesium sulfate (Sibai, 2004).It 
has been found that women with PET had a lower risk 
of progression to eclampsia and a lower mortality rate 
when treated with magnesium sulphate. For 
prophylaxis, MgSO4 has been shown to be superior to 
diazepam, phenytoin, nimodipine and placebo (Altman 
et al, 2002). 
MgSO4 is given as a 4g intravenous loading dose, 
immediately followed by 10g intramuscularly and then 
by 5g every 4 hours in alternating buttocks or a loading 
dose of 4g followed by a maintenance infusion of 1 to 2 
g/h by controlled infusion pump. The clinical effect and 
the toxicity of MgSO4 depends on its serum levels. For 
treatment of eclamptic seizures, a concentration of 1.8 – 
3.0 mmol/L should be achieved. Magnesium is excreted 
mainly by the kidney with the half-life being 4.66 hours 
(Idama and Lindow, 1998).  
The free magnesium diffuses into the extravascular- 
extra cellular space, bone and across the placenta and 
foetal membranes into the amniotic fluid and the foetus 
(Hallak and Cotton, 1993). 
Neonates born to mothers treated with MgSO4 for 
severe PET and eclampsia may be born with significant 
high levels of magnesium concentration ranging from 3 
– 11 mmol/L (Lipsitz and English, 1967). 
The APGAR (Activity Pulse Grimace Appearance 
Respiration) score was invented in 1952 as a means of 
quickly assessing the health of newborns. It is 
calculated at 1 minute and 5 minutes after birth by 
scoring the heart rate, respiratory rate, muscle tone, 
skin colour and reflex response with each receiving a 
score of 0-2 d.  A score of 10 means the infant is healthy 
while a low score is predictive of high morbidity and 
mortality rates.  
Studies done at Pumwani Maternity hospital the 
research area (Bansal, 1985), have shown neonates 
born to mothers with severe PET and eclampsia were 
underweight at birth and had low APGAR scores. This 
could be attributed to in utero magnesium sulphate 
exposure used for the management of PET and 
eclampsia in their mothers. Hypermagnesemia in the 
neonate has been shown to be associated with asphyxia 
and decreased serum calcium levels on long term use. 
Neonatal neurological depression may occur with 
respiratory depression, loss of reflexes and muscle 
weakness. This may result in low APGAR scores. Thus 
the study aimed at finding out whether there was a link 
between the low birth weights and low APGAR scores in 
neonates of mothers with preeclampsia/eclampsia and 
the in utero magnesium sulphate exposure when 
mothers were treated with magnesium sulphate. 
2. Methodology 
2.1 Study design and study area 
The research design was a quasi-experimental study. 
The study was conducted at Pumwani Maternity 
hospital, the biggest government maternity hospital in 
East and Central Africa catering for both low and middle 
income earners. It has one labor ward, two ante-natal 
wards and 5 post-natal wards. Pumwani maternity 
hospital has an average of 70 deliveries per day, 30,000 
per year. 
2.2 Target population 
 The test population was made up of neonates of 
mothers who had been treated with magnesium 
sulphate for severe preeclampsia. These were 
compared to the controls who were neonates of 
mothers who had preeclampsia but were treated with 
other drugs other than MgSO4 such as nifedipine, 
hydralazine and methyldopa.  
2.3 Sampling 
Sample size was calculated using the Karl Fischer’s 
method. With an incidence of 1.8% (Osungbade and Ige, 
2011), the desired sample size was 27 mothers and 
their neonates for the tests and 27 mothers and their 
neonates for the controls. Sampling was by convenient 
sampling method due to the limited number of patients 
presenting with severe PET and eclampsia. 
2.4 Inclusion/exclusion criteria 
The patients included in the study for the test arm had 
to be patients diagnosed with severe PET and eclampsia 
(Sibai, 2005) and on MgSO4 therapy. For the control 
arm, the patients had to be diagnosed with 
preeclampsia but not on treatment with MgSO4. All 
patients had to have given birth to live babies who were 
also included in the study. 
Patients receiving magnesium for treatment of any 
other ailments or suffering from conditions which might 
present with symptoms similar to hypermagnesemia i.e. 
adrenal insufficiency, renal failure, hypocalcaemia, 
hypokalemia, hypoparathyroidism, hypothyroidism and 
rhabdomyolysis which may precipitate 
hypermagnesemia were excluded from the study 
Patients from whom samples could not be obtained for 
both mother and baby or who refused to give consent 
were excluded from the study. 
2.5 Data collection 
Data was collected after a successful pilot study had 
been carried out. Patient's particulars were filled in a 
data collection form by the investigators. The signs and 
symptoms used to diagnose the patient were also noted 
from the patient file and confirmed with the patient. 
The patients were observed for any signs indicating 
toxicity like increase or decrease of seizures, urine 
output, presence or absence of deep tendon reflexes.  
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With assistance from the nurses in the labour ward, 
blood samples were drawn from the mothers some 2-3 
hours after a loading dose of MgSO4 had been given to 
allow for the apparent volume of distribution to be 
reached (Lu et al, 2000). Blood samples were also 
collected from the neonate at birth. For the control 
group samples were obtained from the mother an hour 
after the oral drugs had been given and from the 
neonates at birth. The samples were then centrifuged 
and the serum obtained analyzed. 
2.6 Data analysis 
The serum urea and electrolyte levels were measured 
and reference made to the normal ranges. The mean 
magnesium levels were determined and the deviation 
from reference ranges determined. The serum 
magnesium levels in the exposed neonates were 
measured and compared to serum magnesium in 
neonates not exposed to MgSO4 and these were also 
correlated with the maternal serum magnesium levels. 
The APGAR scores and birth weight for the neonates 
exposed were compared to those of the non-exposed 
group. 
2.7 Ethical considerations 
Approval to carry out the study was given by the 
Kenyatta National Hospital/University of Nairobi Ethics 
Committee and the Pumwani Maternity Hospital 
administration as per the letter referenced KNH-
ERC/A/165. Confidentiality of the respondents as well 
as of all records evaluated was observed. No patient 
names were used. All patients were adequately treated 
and any their neonates managed for any untoward 
symptoms before discharge. 
3.  Results  
Study participants characteristics 
The mean age of mothers in the test group was 25.3 
years (SD 4.6) compared to a mean age of 25.7 years 
(SD 4.7) years among controls. The modal age group in 
the test group was 21- 25 years (n=11) and in the 
control group 26-30 years (n=10). There was no 
significant difference in the mean age of mothers in the 
two groups (t = 0.29; p = 0.76). 
The median gestation age in the test group was 38 
weeks and the range was 34 to 40 weeks while that of 
the control group was 39 weeks and 36 to 41 weeks 
respectively. Mothers receiving magnesium sulphate 
treatment were mostly delivered during week 37-38 
(48.2%) while most (48.2%) mothers in the control 
group delivered at 39-41 weeks. 
Maternal hypertension 
The mean diastolic BP among mothers in the test group 
was 115.4 mmHg (SD 12.1) compared to a mean BP of 
98.3 mmHg (SD 5.7) in the control group. The difference 
was statistically significant (p < 0.001). 17 mothers in 
test group had severe hypertension, while there was a 
bimodal distribution of BP measurement in the control 
group; with patients equally likely to have mild 
hypertension (n = 11) or normal blood pressure (n = 
11). 
Maternal and neonatal serum magnesium 
The mean maternal serum magnesium in the test group 
(mean = 2.9 mmol/L, SD = 0.9) was significantly higher 
than the control group (mean = 2.3 mmol/L, SD = 0.6, p 
= 0.008).  
The mean neonatal serum magnesium in the test group 
(mean = 3.0 mmol/L, SD = 1.0) was significantly higher 
than the control group (mean = 2.3 mmol/L, SD = 0.6, p 
= 0.008).  
Maternal urea and electrolytes levels 
There were statistically significant differences in serum 
sodium, urea and creatinine levels in the test and 
control groups (Table 1). Serum sodium was higher in 
control group while creatinine and urea were higher in 
the test group. Maternal serum levels of potassium, 
chloride and calcium did not show significant 
differences between the test and control groups. 
Neonatal urea and electrolytes levels 
There were significant differences between tests and 
controls in levels of serum urea (p = 0.007) and chloride 
(p = 0.017). Urea levels were significantly higher in the 
test group compared to the control group (mean = 4.0 
mmol/L versus 2.9 mmol/L), while mean chloride levels 
were 99.4 mmol/L for the test group vs. 97.2 mmol/L 
for the control group (Table 1). 
Neonatal APGAR scores 
There was no significant difference between the APGAR 
scores of the neonatal test and control groups. 89 % of 
the neonates in the test had a score of 7-8 at 1 minute 
and at 5 minutes 59% had a score of 9-10. In the control 
group, 59% had a score of 7-8 at 1 minute while at 5 
minutes, 59 % had a score similar to that of the test 
group (Figure 1). 
Neonatal birth weight 
74% of the neonates in the test group were 
underweight with only 19% being of normal birth 
weight. In the control group, only 41% were 
underweight with 52% being of normal birth weight.7% 
of neonates in both groups were overweight. The 
median birth weight in the test group was 2.2 kg (IQR 
1.8 to 3.0) compared to a median of 3 kg (IQR 2.3 to 3.6) 
in the control group. There was a statistically significant 
difference in birth weight of neonates in the test and 
intervention groups, Mann Whitney test p value = 0.003. 
Infant birth weight was not significantly associated with 
neonatal serum magnesium sulphate levels after 
adjusting for the test group. The mean serum 
magnesium level was 0.66 mmol/L higher in neonates 
in the test compared to control group (p = 0.008). The 
neonatal magnesium serum levels increased by 0.07 
mmol/L for each additional kilogram of birth weight but 
this increase was not significant (p = 0.605). 
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Table 1: Maternal and Neonatal urea and electrolytes in test and control groups 
 Maternal  Neonatal 
 Tests Controls   Tests Controls  
 Mean 
(mmol/L) 
SD 
Mean 
(mmol/L) 
SD P value 
 Mean 
(mmol/L) 
SD 
Mean 
(mmol/L) 
SD P value 
Sodium 135.9 3.8 138.4 3.6 0.015  138.6 6.0 138.4 4.4 0.883 
Potassium 4.5 1.6 4.3 0.8 0.495  5.1 1.6 4.9 0.7 0.689 
Chloride 99.6 3.8 98.8 2.3 0.371  99.4 3.2 97.2 3.2 0.017 
Urea 3.3 1.7 2.6 0.8 0.043  4.0 1.8 2.9 1.0 0.007 
Creatinine 89.8* 24.7 71.5* 23.0 0.008  99.0* 27.6 82.1* 37.0 0.067 
Calcium 2.0 0.4 1.9 0.3 0.629  2.4 0.4 2.3 0.3 0.241 
*: µmol/L 
     Figure 1: Neonatal APGAR scores  
 
Correlation between maternal and neonatal serum 
magnesium levels 
There was a positive correlation between maternal and 
neonatal serum magnesium levels in both the test and 
control groups. The correlation was stronger in the test 
group (r = 0.56, p = 0.003) compared to the control 
group (r = 0.35, p = 0.087). 
None of the patients developed any signs which would 
have signified toxicity (seizures, urine output, presence 
or absence of deep tendon reflexes) indicating that the 
magnesium sulphate levels in the serum were well 
within the therapeutic range of 1.8 -3 mmol/L. 
4. Discussion 
MgSO4 is the recommended first-line option for the 
treatment and prevention of eclamptic seizures (Altman 
et al, 2002). Accordingly, in our study, patients 
presenting with severe PET (headache, oedema, blurred 
vision, confusion and a diastolic BP above 110 (Sibai, 
2003; Cooray et al, 2004) were first given a loading 
dose of 4g of MgSO4 then an infusion of 1g /hour as a 
maintenance dose.70% of the mothers in the test group 
presented and delivered at a gestation age below 38 
weeks as compared to 11% in the control group. This is 
in line with studies that recommend delivery as the 
definitive treatment for severe preeclampsia after 34 
weeks (Wagner, 2004; Sibai, 2005). 
The serum magnesium levels were found to be 
significantly high in the test group as compared to the 
control group. For treatment of eclamptic seizures, a 
concentration of 1.8 – 3.0 mmol/L should be achieved 
(Idama and Lindow, 1998). In this study the serum level 
of magnesium were well within the recommended 
levels for treatment and not elevated to toxic levels. 
Maternal serum urea and creatinine were found to be 
elevated in the mothers in the test group. Serum 
creatinine levels are used as a marker for kidney injury. 
This is significant because MgSO4 is excreted through 
the renal route  and in view of the damage caused to the 
kidney by the disease, magnesium toxicity could occur. 
There is an increased risk for development of kidney 
injury after preeclampsia and eclampsia (McDonald et 
al, 2010). In eclampsia, abnormalities in blood urea 
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nitrogen and serum creatinine among other findings are 
statistically significant and thus serum creatinine levels 
in eclamptic patients should be monitored (Sibai et al, 
1982; Ries et al, 2000).  
Serum calcium levels in the controls were lower than in 
the test group. Low calcium levels in pre-eclamptic 
women not on treatment with MgSO4 have been found 
previously. After magnesium therapy the levels are 
raised indicating that ionized calcium levels appeared to 
be tightly regulated in the presence of elevated serum 
magnesium levels (Mason et al, 1996). 
The neonatal serum magnesium levels in our study 
correlated with the maternal serum magnesium levels. 
The levels in the neonatal test group were higher than 
in the control group. There is transfer of magnesium 
from maternal circulation into the foetal blood (Hallak 
and Cotton, 1993). An increase in magnesium serum 
levels in both mother and foetus after administration 
occurs (Chelsey and Tepper, 1957). Such newborns of 
mothers exposed to MgSO4 have elevated serum 
magnesium levels ranging from 3-11 mmol/L 
(Widdowson and Mccance, 1965).  
The serum levels of all electrolytes were elevated in the 
neonatal test group as compared to the levels in the 
control group. The urea levels were significantly 
elevated. The high electrolyte levels could be explained 
by the fact that at birth, renal blood flow is low and the 
immature kidney has limited adaptability in case of 
excess administration of drugs and thus a higher risk of 
toxicity. In preterm neonates born at 26- 34 weeks 
gestation age, the increase in the glomerular filtration 
rate is limited because of incomplete nephrogenesis. 
Thus clearance of drugs from the circulation is limited 
resulting in elevated serum levels 
(CPMP/PEG/35132/03, 2004). 
In our study the serum creatinine was found to be 
elevated in the test group. Creatinine levels are used as 
a marker for kidney function. Serum creatinine has been 
shown to be elevated in the first days of life reflecting 
maternal creatinine and a low intrinsic glomerular 
filtration rate. The lower the gestation age at birth, the 
more elevated is the serum creatinine. Because the 
neonates in the test group were born before term, this 
could explain the elevated serum creatinine levels. 
The neonatal serum calcium levels in both groups of our 
study were higher than the maternal serum calcium 
levels. Studies have shown active transfer of calcium 
from the mother to the neonate during the last 
trimester of pregnancy whereby the cord calcium levels 
are higher than the maternal serum calcium levels 
(Schauberger and Pitkin, 1979). In our study, neonatal 
serum calcium levels in the test group were slightly 
higher than in the control group but not significantly 
different.  Similar results to our study have been 
reported (Donovan E.F. et al, 1980). A rise in serum 
magnesium levels inhibits secretion of parathyroid 
hormone which results in increased urinary excretion of 
calcium (MacIntyre et al, 1963). In a study of five 
newborn infants whose mothers had been treated with 
IV magnesium sulfate for periods ranging from 5 to 14 
weeks, radiographic bony abnormalities in two of the 
infants were noted (Lamm et al, 1988). Foetal 
hypermagnesemia due to long term treatment with 
magnesium was found to depress parathyroid hormone 
release resulting in foetal hypocalcaemia (Savory and 
Monif, 1971). No neonatal symptoms have been 
associated with either calcium levels (Donovan et al, 
1980). 
The neonatal serum potassium levels in both groups 
were found to be higher than the maternal serum 
potassium levels while the serum sodium levels were 
found to be lower in the neonates. There is 
physiological hyponatremia and hyperkalemia in 
healthy newborns which is highly suggestive of 
functional hypoaldosteronism (Martinerie et al, 2009). 
This may be due to the adaptive process from 
intrauterine aquatic environment where renal sodium 
reabsorption is dispensable, to life outside the uterus 
where strict sodium control by the kidney is essentials. 
In our study the serum potassium levels in the test 
group were slightly higher than in the control group. 
Higher aldosterone and potassium levels in preterm 
newborns as compared to term healthy newborns have 
been demonstrated (Nader and Procianoy, 1996; 
Semama et al, 2007; Mildenberger and Versmold, 2002). 
There was a statistically significant difference in birth 
weight of neonates in the two groups. Low birth weight 
has been found in a neonate with severe 
hypermagnesemia (Hyun et al, 2011). But there was no 
correlation between the birthweight and the serum 
magnesium levels which implies that the low birth 
weight was more of a function of the disease than the 
effect of administered magnesium sulphate. 
5. Conclusion 
Maternally administered magnesium sulphate raises 
urea and creatinine levels to significant levels in 
mothers. Calcium levels are also raised while in mothers 
not receiving magnesium sulphate they were slightly 
lower. In neonates the urea and chloride levels are 
elevated to significant levels while the calcium and 
potassium levels are not significantly elevated. We 
suggest monitoring of both in the immediate post-
partum period. 
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